Junyi Yang
Junyi Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Baoqi Zhang
Department of Surgery, Linyi Central Hospital, Linyi, Shandong, China
2 shared publicationsJunfa Gao
Laboratory Department, Linyi Central Hospital, Yishui, Shandong, China
2 shared publicationsYanli Gao
Department of Clinical Pharmacy, Linyi Central Hospital, Linyi, Shandong, China
2 shared publicationsYongjing Ju
Department of Pharmaceutical, Central Hospital of Linyi City, Yishui, Shandong, China
2 shared publicationsChuanlan Gu
Urology department, Central Hospital of Linyi City , Linyi , Yishui Shandong , China
1 shared publicationDuzhen Zhang
Department Ophthalmology, Central Hospital of Linyi City, Yishui, Shandong, China
1 shared publication
Latest Publications
- 30 August 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (9) , 1011-1016
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder
Olanzapine (OLZ) is one of the most effective antipsychotic agents, however, its clinical utility has been limited by weight gain. Samidorphan (SAM) is aμ-opioid receptor antagonist and it can redu...
- 30 August 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (9) , 1011-1016
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder
Olanzapine (OLZ) is one of the most effective antipsychotic agents, however, its clinical utility has been limited by weight gain. Samidorphan (SAM) is aμ-opioid receptor antagonist and it can redu...
- 3 July 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (7) , 799-803
Dasiglucagon for treating severe hypoglycemia in patients with diabetes
Diabetic patients are prone to hypoglycemia when treated with insulin. Dasiglucagon is a water-soluble and ready-to-use glucagon analog developed for treating hypoglycemia in patients with diabetes...
- 3 July 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (7) , 799-803
Dasiglucagon for treating severe hypoglycemia in patients with diabetes
Diabetic patients are prone to hypoglycemia when treated with insulin. Dasiglucagon is a water-soluble and ready-to-use glucagon analog developed for treating hypoglycemia in patients with diabetes...
- 1 February 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (2) , 139-145
Evinacumab for the treatment of homozygous familial hypercholesterolemia
Hypercholesterolemia is mainly caused by abnormal lipoprotein metabolism and can increase the risk of cardiovascular disease. Angiopoietin-like protein 3 (ANGPTL3) can increase low-density lipoprot...
- 1 February 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (2) , 139-145
Evinacumab for the treatment of homozygous familial hypercholesterolemia
Hypercholesterolemia is mainly caused by abnormal lipoprotein metabolism and can increase the risk of cardiovascular disease. Angiopoietin-like protein 3 (ANGPTL3) can increase low-density lipoprot...
- 11 January 2021
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (10) , 1283-1289
Oliceridine for the Management of Acute Postoperative Pain
To review the pharmacological characteristics, clinical evidence, and place in the management of acute postoperative pain severe enough to require an intravenous opioid. A comprehensive literature search was conducted in PubMed (January 2000 to December 1, 2020). Key search terms included oliceridine or acute postoperative pain. Other sources were derived from product labeling and ClinicalTrials.gov. All English-language articles identified from the data sources were reviewed and evaluated. Phase I, II, and III clinical trials were included. Oliceridine is a novel selective µ-receptor G-protein pathway modulator. It has the property of activating G-protein signaling while causing low β-arrestin recruitment to the µ-receptor. Intravenous oliceridine showed statistically superior analgesia than placebo in patients with moderate or severe pain after surgery, with a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects, compared with morphine. The analgesic capacity of oliceridine is at least comparable to that of morphine at clinically relevant dosages, with a rapid onset of action. Also, it may be associated with a lower incidence of adverse events at dosing regimens associated with comparable analgesia. These data suggest that oliceridine may provide an important new treatment option for the management of moderate to severe postoperative pain where an intravenous opioid is warranted. Oliceridine has obvious analgesic effects in patients with moderate or severe pain after surgery; additionally, it has a favorable safety and tolerability profile.
- 11 January 2021
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (10) , 1283-1289
Oliceridine for the Management of Acute Postoperative Pain
To review the pharmacological characteristics, clinical evidence, and place in the management of acute postoperative pain severe enough to require an intravenous opioid. A comprehensive literature search was conducted in PubMed (January 2000 to December 1, 2020). Key search terms included oliceridine or acute postoperative pain. Other sources were derived from product labeling and ClinicalTrials.gov. All English-language articles identified from the data sources were reviewed and evaluated. Phase I, II, and III clinical trials were included. Oliceridine is a novel selective µ-receptor G-protein pathway modulator. It has the property of activating G-protein signaling while causing low β-arrestin recruitment to the µ-receptor. Intravenous oliceridine showed statistically superior analgesia than placebo in patients with moderate or severe pain after surgery, with a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects, compared with morphine. The analgesic capacity of oliceridine is at least comparable to that of morphine at clinically relevant dosages, with a rapid onset of action. Also, it may be associated with a lower incidence of adverse events at dosing regimens associated with comparable analgesia. These data suggest that oliceridine may provide an important new treatment option for the management of moderate to severe postoperative pain where an intravenous opioid is warranted. Oliceridine has obvious analgesic effects in patients with moderate or severe pain after surgery; additionally, it has a favorable safety and tolerability profile.
- 27 November 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (9) , 1167-1171
Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders
To review the pharmacological characteristics, clinical evidence, and place in therapy of satralizumab for the treatment of neuromyelitis optica spectrum disorders (NMOSDs). A comprehensive literature search was conducted in PubMed (January 2000 to October 15, 2020). Key search terms included satralizumab and neuromyelitis optica spectrum disorders. Other sources were derived from product labeling and ClinicalTrials.gov. All English-language articles identified from the data sources were reviewed and evaluated. Phase I, II, and III clinical trials were included. NMOSD is an autoimmune disease characterized by inflammatory lesions in the optic nerves and spinal cord. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. Phase III trials showed that protocol-defined relapse was 30% for satralizumab and 50% for placebo (P = 0.018) when patients with NMOSD were treated with satralizumab monotherapy; protocol-defined relapse was 20% for satralizumab and 43% for placebo (P = 0.02) when satralizumab was added to immunosuppressant treatment. Satralizumab is generally well tolerated, with common adverse effects including injection-related reaction. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients.
- 27 November 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (9) , 1167-1171
Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders
To review the pharmacological characteristics, clinical evidence, and place in therapy of satralizumab for the treatment of neuromyelitis optica spectrum disorders (NMOSDs). A comprehensive literature search was conducted in PubMed (January 2000 to October 15, 2020). Key search terms included satralizumab and neuromyelitis optica spectrum disorders. Other sources were derived from product labeling and ClinicalTrials.gov. All English-language articles identified from the data sources were reviewed and evaluated. Phase I, II, and III clinical trials were included. NMOSD is an autoimmune disease characterized by inflammatory lesions in the optic nerves and spinal cord. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. Phase III trials showed that protocol-defined relapse was 30% for satralizumab and 50% for placebo (P = 0.018) when patients with NMOSD were treated with satralizumab monotherapy; protocol-defined relapse was 20% for satralizumab and 43% for placebo (P = 0.02) when satralizumab was added to immunosuppressant treatment. Satralizumab is generally well tolerated, with common adverse effects including injection-related reaction. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients.
- 2 August 2020
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 16 (8) , 739-743
Teprotumumab for the treatment of thyroid eye disease
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which ...
- 2 August 2020
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 16 (8) , 739-743
Teprotumumab for the treatment of thyroid eye disease
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which ...
- 22 June 2020
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 18 (7) , 373-380
Bempedoic acid for the treatment of hypercholesterolemia
Although several lipid-lowering drugs are available, they are not sufficient for some patients. Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase inhibitor indicated for the t...
- 22 June 2020
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 18 (7) , 373-380
Bempedoic acid for the treatment of hypercholesterolemia
Although several lipid-lowering drugs are available, they are not sufficient for some patients. Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase inhibitor indicated for the t...
- 23 January 2020
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 13 (2) , 79-84
Pitolisant for treating patients with narcolepsy
Introduction: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Pitolisant is a first-in-class drug acting on histamine 3 receptors and indicated for the treatment of narcolepsy. This article aims to review pitolisant. Areas covered: In this paper the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy and safety of pitolisant was introduced, and the development course of drugs for treating narcolepsy is also briefly described. We performed a systematic review of the literature using PubMed and the following keywords were used: “pitolisant” and “narcolepsy”, “cataplexy” and “excessive daytime sleepiness” and “histamine 3 receptor”. Expert opinion: Pitolisant is a histamine 3 receptor antagonist/inverse agonist. It can activate histamine release in the brain and enhances wakefulness. Clinical studies showed that pitolisant significantly decreased excessive daytime sleepiness and cataplexy rate versus placebo. Pitolisant was well tolerated, common adverse reactions were headache,insomnia, nausea, and anxiety.
- 23 January 2020
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 13 (2) , 79-84
Pitolisant for treating patients with narcolepsy
Introduction: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Pitolisant is a first-in-class drug acting on histamine 3 receptors and indicated for the treatment of narcolepsy. This article aims to review pitolisant. Areas covered: In this paper the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy and safety of pitolisant was introduced, and the development course of drugs for treating narcolepsy is also briefly described. We performed a systematic review of the literature using PubMed and the following keywords were used: “pitolisant” and “narcolepsy”, “cataplexy” and “excessive daytime sleepiness” and “histamine 3 receptor”. Expert opinion: Pitolisant is a histamine 3 receptor antagonist/inverse agonist. It can activate histamine release in the brain and enhances wakefulness. Clinical studies showed that pitolisant significantly decreased excessive daytime sleepiness and cataplexy rate versus placebo. Pitolisant was well tolerated, common adverse reactions were headache,insomnia, nausea, and anxiety.
- 28 August 2019
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (9) , 851-857
Risankizumab for the treatment of psoriasis
Introduction: The interleukin (IL)-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis. This article aims to review risankizumab and provides reference for clinicians. Areas covered: The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, safety of risankizumab was introduced in this paper. A PubMed search using the terms ‘risankizumab,’ ‘IL-23,’ ‘p19 subunit,’ and ‘psoriasis,’ was performed, and the results were screened for the most relevant English language publications. Expert opinion: Risankizumab is a humanized IgG monoclonal antibody that binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Clinical trials showed that risankizumab was significantly more effective than ustekinumab. Risankizumab was well tolerated, upper respiratory tract infection was the common adverse reactions. Therefore, the market of risankizumab provides an important therapeutic means for psoriasis.
- 28 August 2019
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (9) , 851-857
Risankizumab for the treatment of psoriasis
Introduction: The interleukin (IL)-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis. This article aims to review risankizumab and provides reference for clinicians. Areas covered: The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, safety of risankizumab was introduced in this paper. A PubMed search using the terms ‘risankizumab,’ ‘IL-23,’ ‘p19 subunit,’ and ‘psoriasis,’ was performed, and the results were screened for the most relevant English language publications. Expert opinion: Risankizumab is a humanized IgG monoclonal antibody that binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Clinical trials showed that risankizumab was significantly more effective than ustekinumab. Risankizumab was well tolerated, upper respiratory tract infection was the common adverse reactions. Therefore, the market of risankizumab provides an important therapeutic means for psoriasis.
- 19 June 2019
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (8) , 723-728
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. The purpose of this paper is to review solriamfetol. Areas covered: The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of solriamfetol are introduced in this paper. Expert opinion: Solriamfetol can bind to dopamine and norepinephrine transporters and inhibit reuptake of dopamine and norepinephrine. Clinical trials showed that solriamfetol could significantly improve the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy. Solriamfetol was well tolerated. Very common adverse reactions were headache, nausea, decreased appetite, insomnia, and anxiety.
- 19 June 2019
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (8) , 723-728
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. The purpose of this paper is to review solriamfetol. Areas covered: The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of solriamfetol are introduced in this paper. Expert opinion: Solriamfetol can bind to dopamine and norepinephrine transporters and inhibit reuptake of dopamine and norepinephrine. Clinical trials showed that solriamfetol could significantly improve the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy. Solriamfetol was well tolerated. Very common adverse reactions were headache, nausea, decreased appetite, insomnia, and anxiety.